Business Context and Reporting Period
This Form 8-K Current Report was filed by Gossamer Bio, Inc. on April 17, 2021, covering events occurring on that date. The company is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on the Nasdaq Global Select Market under the symbol "GOSS."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance data.
Material Changes
The primary material change reported is the departure of a senior executive:
- Luisa Salter-Cid, Ph.D. resigned from her position as Chief Scientific Officer.
- The resignation is effective as of April 30, 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the executive departure. A press release dated April 20, 2021, is included as an exhibit but its content is not detailed in the filing text provided.
Investor Verification Checklist
- Verify the effective date of the Chief Scientific Officer's resignation (April 30, 2021).
- Review the attached press release (Exhibit 99.1) for details on the transition plan or replacement for the Chief Scientific Officer role.
- Confirm if this departure impacts ongoing clinical trials or scientific strategy, as this information is not explicitly stated in the 8-K text.